Ciliary Neurotrophic Factor clinical trials
Also written NT-501.
How each study uses Ciliary Neurotrophic Factor is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Get an email when these change. Save the Ciliary Neurotrophic Factor studies recruiting or about to start — once a week, free: studies that open, close, add sites or post results.
See an example email
Example · made-up studies
Breast cancer · Recruiting: 2 came in, 3 changed
What changed in your alerts, Oct 31 – Nov 6:
A study of drug A after surgery for early breast cancer
Came in · now Recruiting
Drug B with hormone therapy in advanced breast cancer
Changed
· Sites: 4 added, including Seoul and Busan
· Enrollment: 300 → 450 participants
Exercise during chemotherapy
Now Active, not recruiting
One email a week for all your alerts. Stop any time.
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
17 studies that test it; most in 2007 (3)
| Year | Studies |
|---|---|
| 2003 | 1 |
| 2007 | 3 |
| 2011 | 3 |
| 2012 | 2 |
| 2014 | 1 |
| 2016 | 1 |
| 2017 | 2 |
| 2018 | 1 |
| 2021 | 2 |
| 2025 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 11 · Other 6
Neurotech Pharmaceuticals (11) · Stanford University (2) · National Eye Institute (NEI) (2) · Jeffrey L Goldberg (2)
Often tested with
Tested in the same studies.
Revakinagene taroretcel (1)
Studies
Open first, then newest update. How each study uses Ciliary Neurotrophic Factor is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 17
- Phase 4 Study: Long-term Safety and Efficacy of NT-501 in MacTel Type 2, Including Sham Procedure ParticipantsRecruitingPhase 4Neurotech PharmaceuticalsNCT06971939Written as NT-501/revakinagene taroretcel-lwey
- Study of NT-501 Encapsulated Cell Therapy for Glaucoma Neuroprotection and Vision RestorationActive, not recruitingPhase 2Stanford UniversityNCT02862938Written as NT-501 ECT implant
- Dual Intravitreal Implantation of NT-501 Encapsulated Cell Therapy for GlaucomaActive, not recruitingPhase 2Stanford UniversityNCT04577300Written as NT-501
- Extension Study of NT-501 Ciliary Neurotrophic Factor (CNTF) Implant for Macular Telangiectasia (MacTel)CompletedPhase 2Neurotech PharmaceuticalsNCT03071965Written as Ciliary neurotrophic factor (CNTF)
- A Study of Encapsulated Cell Technology (ECT) Implant for Participants With Early Stage Retinitis PigmentosaCompletedPhase 2Neurotech PharmaceuticalsNCT00447980Written as NT-501
- A Study of an Encapsulated Cell Technology (ECT) Implant for Patients With Atrophic Macular DegenerationCompletedPhase 2Neurotech PharmaceuticalsNCT00447954Written as High Dose NT-501 implant
- Safety Study to Evaluate Bilateral CNTF Implants in Subjects With MacTel Type 2CompletedPhase 2Neurotech PharmaceuticalsNCT04729972Written as NT-501 CNTF implant
- A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol BCompletedPhase 3Neurotech PharmaceuticalsNCT03319849Written as NT-501
- A Study to Determine the Safety and Efficacy of NT-501 in Macular Telangiectasia Type 2 - Protocol ACompletedPhase 3Neurotech PharmaceuticalsNCT03316300Written as NT-501
- A Study of Encapsulated Cell Technology (ECT) Implant for Patients With Late Stage Retinitis PigmentosaCompletedPhase 2Neurotech PharmaceuticalsNCT00447993Written as Low Dose NT-501
- Retinal Imaging in CNTF -Releasing Encapsulated Cell Implant Treated Patients for Early-stage Retinitis PigmentosaCompletedPhase 2Neurotech PharmaceuticalsNCT01530659Written as NT-501
- A Phase 2 Multicenter Randomized Clinical Trial of CNTF for MacTelCompletedPhase 2Neurotech PharmaceuticalsNCT01949324Written as Ciliary neurotrophic factor (CNTF)
- Ciliary Neurotrophic Factor (CNTF) Safety Trial in Patients With Macular Telangiectasia (Mactel)CompletedPhase 1Neurotech PharmaceuticalsNCT01327911Written as NT-501 implant
- CNTF Implants for CNGB3 AchromatopsiaCompletedPhase 1/2National Eye Institute (NEI)NCT01648452Written as NT-501 CNTF-releasing implant
- NT-501 CNTF Implant for Ischemic Optic Neuropathy: Safety, Neuroprotection and NeuroenhancementCompletedPhase 1Jeffrey L GoldbergNCT01411657Written as NT-501 CNTF Implant
- NT-501 CNTF Implant for Glaucoma: Safety, Neuroprotection and NeuroenhancementCompletedPhase 1Jeffrey L GoldbergNCT01408472Written as NT-501 CNTF Implant
- Evaluation of Safety of Ciliary Neurotrophic Factor Implants in the EyeCompletedPhase 1National Eye Institute (NEI)NCT00063765Written as Ciliary Neurotrophic Factor Implant NT-501